Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Cardiff Oncology Q3 EPS $(0.17) Beats $(0.20) Estimate, Sales $120.000K Beat $112.500K Estimate

Author: Benzinga Newsdesk | November 06, 2025 04:37pm
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.20) by 15.42 percent. This is a 32 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $120.000 thousand which beat the analyst consensus estimate of $112.500 thousand by 6.67 percent. This is a 27.27 percent decrease over sales of $165.000 thousand the same period last year.

Posted In: CRDF


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist